Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Magnetic Resonance Imaging (MRI).
- Who it may be relevant to
- Registry conditions: Diffusion Magnetic Resonance Imaging, Brain White Matter Diseases. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Role of Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases
Overview
To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.
Detailed description
Brain white matter diseases (WMDs) are a group of neurological conditions that involve changes to the brain's white matter, often leading to cognitive, motor, and sensory impairments.
Diffusion Magnetic Resonance Imaging (dMRI), has emerged as a powerful non-invasive imaging tool for evaluating microstructural changes in brain white matter. This protocol aims to investigate the role of dMRI in the early identification and characterization of brain white matter diseases, focusing on its potential for detecting abnormalities before the onset of overt clinical symptoms.
Diffusion-weighted imaging (DWI), one of the first advanced magnetic resonance imaging (MRI) techniques, has rapidly ascended on the basis of its applicability in strokes and some infectious diseases. Restricted diffusion is significant information in the context of vascular ischemia, helping to delimit the brain-damaged area
Interventions
- Other Magnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
Primary outcome measures
- Sensitivity of diffusion magnetic resonance imaging [Time frame: Immediately after diffusion magnetic resonance imaging (Up to 1 hour)]
Eligibility criteria
Inclusion criteria
- Adults aged 18-80 years.
- Clinical suspicion of early-stage white matter disease.
- No prior diagnosis of significant neurological disorders (e.g., stroke, brain tumors).
- Ability to provide informed consent.
Exclusion criteria
- Pregnancy or breastfeeding.
- Contraindications for magnetic resonance imaging (MRI) (e.g., metal implants, pacemakers).
- Severe psychiatric or cognitive impairment that prevents participation.
- Control Group: Healthy individuals without any clinical history of neurological diseases, matched by age and sex to the patient cohort.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Egypt · 1 center
- General Authority for Teaching Hospitals and Institutes — Cairo
Identifiers
NCT: NCT07108712 · HD000235